Background: The degree of variability in prostate-specific antigen (PSA) measurements is important for interpreting test results in screening programs, and particularly for interpreting the significance of changes between repeated tests. This study aimed to determine the long-term intra-individual variation for PSA in healthy men.
Methods: A randomly selected cohort of men in a biennial prostate cancer screening program (ERSPC) conducted in Sweden from 1995-1996 to 2001-2002. We studied men who had total PSA (tPSA) levels < 2.0 ng/ml in 2001-2002. This included 791 men with tPSA < or = 0.61 ng/ml (group A), 1,542 men with tPSA < or = 0.99 ng/ml (group B), and 1,029 men with tPSA 1.00-1.99 ng/ml (group C). The intra-individual variability of free PSA (fPSA) and tPSA was assessed by calculating coefficients of variation (CV) for each individual's PSA measurements from the first and second round of screening (1995-1996 and 1997-1998).
Results: Intra-individual CV (geometric means) for tPSA were 13.7%, 12.7%, and 11.5% in groups A, B, and C, respectively. Corresponding CVs for fPSA were significantly lower, ranging from 12.1% to 10.4%. The estimated biological variation of tPSA and fPSA in groups A to C were 12.5%, 11.4%, 10.0% and 9.7%, 7.8%, 7.5%, respectively.
Conclusions: In healthy men with PSA levels less than 2 ng/ml, the natural long-term variability for tPSA was less than 14%, and with 95% probability, a change in tPSA greater than 30% indicates a change beyond normal random variation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1951509 | PMC |
| http://dx.doi.org/10.1002/pros.20286 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between visceral adiposity index and prostate cancer in men aged 40 years and older: a nationwide cross-sectional study.
Aging Male
December 2025
Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Objectives: This study aimed to elucidate the correlation of Visceral Adiposity Index (VAI) with prostate cancer (PCa) among men aged 40 years and older in the United States.
Methods: Analysis included multivariate linear and logistic regression, smoothing curve fitting, and threshold effect evaluation using 2003-2010 National Health and Nutrition Examination Survey (NHANES) data. The stability of this relationship across demographic groups was assessed via subgroup analyses and interaction tests.
Clinical assessment of urinary prostate cancer antigen 3 in Chinese population: a large-scale, prospective and multicenter study.
World J Surg Oncol
December 2024
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: To assess the clinical utility of PCA3 in the diagnostic accuracy, the correlation between PCA3 and biopsy or pathological characteristics and the performance of PCA3 to reduce the unnecessary biopsies in Chinese population.
Methods: A prospective study including patients with indication of prostate biopsies from 4 centers was conducted. All patients underwent PCA3 urine tests and prostate biopsies.
Total Prostate-Specific Antigen (PSA) Testing in Capillary Samples: Proof-of-Principle and Feasibility Study for Home Self-Testing for Prostate Cancer.
J Appl Lab Med
December 2024
Department of Clinical Oncology, Broomfield Hospital, Mid & South Essex NHS Foundation Trust, Chelmsford, Essex, United Kingdom.
Background: There is growing interest in the use of capillary blood sampling (CBS) for testing biochemical analytes owing to the advantages it offers including home surveillance of chronic conditions. In this study, we aimed to determine whether the use of CBS was a viable and feasible method for testing total prostate-specific antigen (TPSA) concentrations in men with prostate disease.
Methods: Men with known prostate disease were recruited from a urology clinic where they were being treated or followed up.
The Predictive Value of tPSA, fPSA, fPSA/tPSA Combined with Ultrasound Parameters in Postoperative Gleason Grading of Prostate Cancer.
Ann Ital Chir
December 2024
Endocrine Tumor Intervention Department, Jinan Central Hospital, Central Hospital Affiliated to Shandong First Medical University, 250013 Jinan, Shandong, China.
Aim: Prostate cancer (PCa) is a common malignant tumor in men. This study aimed to explore the predictive value of serum biomarkers combined with ultrasound parameters for postoperative Gleason grading in PCa.
Methods: This study included 65 PCa patients who underwent transurethral resection of the prostate in our hospital from January 2021 to December 2023.
Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS ≤ 3 MRI.
Eur J Nucl Med Mol Imaging
October 2024
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Article Synopsis
- - The study focuses on improving the diagnosis of clinically significant prostate cancer (csPCa) in men with inconclusive MRI results (PI-RADS ≤ 3) by using a diagnostic model that incorporates [Ga]Ga-PSMA PET/CT scans.
- - Researchers analyzed data from 151 men and found that their model, which combines various PET scan scores and PSA levels, achieved a higher diagnostic performance compared to traditional methods, with an AUC of 0.906.
- - The model can potentially reduce unnecessary biopsies by up to 78% while only missing about 7.8% of csPCa cases, indicating it could significantly enhance clinical decision-making in suspicious prostate cancer cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!